Posted by Michael Wonder on 05 Jun 2025
TGA approves weight loss drug to treat sleep disorder
4 June 2025 - The country’s medicines regulator has approved the use of a GLP-1 weight-loss drug to treat people with sleep apnoea for the first time, broadening the applications for the popular drugs beyond diabetes and heart disease.
Eli Lilly said the TGA had approved the use of its Mounjaro weight-loss drug to treat moderate to severe obstructive sleep apnoea in adults with obesity.
